Across the study period, adverse events were generally consistent with trials of other incretin-based therapies and typically worsened with dose escalation (4 mg, 9 mg, 12 mg, vs
Theres no high-level study to provide an answer, so Dayan always asks his patients to get clearance from their oncology team before taking the medication
The FDA has issued safety communications regarding compounded tirzepatide, including risks of dosing errors and warnings against using salt forms (such as tirzepatide sodium or acetate)
This consultation is perfect for those who feel stuck, arent seeing results, want to switch medications, or simply dont know what the best next step is
It does not replace one
This may be due to other processes such as functional and structural abnormalities also significantly contributing to the development of PLD as we have recently reported 55, 56